Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Use of Insulin in Outpatient Diabetes Management

  • Chapter
  • First Online:
The Diabetes Textbook

  • 4073 Accesses

Abstract

Dosing insulin is like a dance. The insulin dose is initially calculated, and then the blood glucose levels must be evaluated, in order to increase or decrease the insulin dose responsible for that blood glucose value. The goal is not to go chasing after the blood glucose has risen but to prevent its rise. For this, one must carefully take into account the quality and quantity of a given meal (and its carbohydrate content), the activity level, the patient’s health status, and how other medications could affect the blood glucose levels.

In this chapter, we describe the different insulin types and their action times, the clinical indications for insulin initiation, the different insulin regimens, and the adverse effects. We also give insulin storage and injection recommendations.

Having a multidisciplinary team (diabetes educator, dietitian, physician, patient, family support) is key for insulin initiation and adjustment. Starting insulin in the office (first injection) will increase treatment adherence. Having a close follow-up is important. In addition, one must be careful to educate the patient in hypoglycemia prevention, detection, and treatment. It cannot be stressed out enough that self-monitoring of blood glucose (SMBG) and records are keys for a successful insulin therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bethel MA, Feinglos MN. Basal insulin therapy in type 2 diabetes. J Am Board Fam Pract. 2005;18(3):199–204. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15879567.

    Article  Google Scholar 

  2. American Diabetes Association (ADA). Standard of medical care in diabetes - 2017. Diabetes Care. 2017;40(Supplement 1):S4–128.

    Article  Google Scholar 

  3. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive Summary. Endocr Pract. 2017;23(2):207–38. Available from: http://journals.aace.com/doi/10.4158/EP161682.CS.

    Article  Google Scholar 

  4. Tibaldi JM. Evolution of insulin: from human to analog. Am J Med. Elsevier Inc. 2014;127(10):S25–38. Available from: https://doi.org/10.1016/j.amjmed.2014.07.005.

  5. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357(17):1716–30.

    Article  CAS  Google Scholar 

  6. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18):1736–47. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0905479.

    Article  CAS  Google Scholar 

  7. Riddle M, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–6.

    Article  CAS  Google Scholar 

  8. Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet. Springer International Publishing;. 2017;56(5):551–9.

    Article  CAS  Google Scholar 

  9. Origin T, Investigators T. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1203858.

    Article  Google Scholar 

  10. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017; NEJMoa1615692. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1615692.

  11. Becker RHA, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 units z mL 21 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units z mL 21. Diabetes Care. 2015;38(4):637–43.

    CAS  PubMed  Google Scholar 

  12. Bailey T, Dahmen R, Pettus J, Roussel R, Bergmann K, Maroccia M, Nassr N, Klein O, Bolli G, Heise T. Insulin glargine 300 u/ml (gla-300) provides more stable and more evenly distributed steady-state pharmacodynamic/pharmacokinetic profiles compared with insulin degludec in type 1 diabetes (T1DM). Endocr Pract. 2017;23(1):48A. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L615078040.

    Google Scholar 

  13. Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S, Haahr HL. Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017;19(7):1032–9.

    Article  CAS  Google Scholar 

  14. Sorli C. New developments in insulin therapy for type 2 diabetes. Am J Med. Elsevier Inc. 2014;127(10):S39–48. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002934314005865.

  15. Klonoff DC. Afrezza inhaled insulin. J Diabetes Sci Technol. 2014;8(6):1071–3. Available from: http://journals.sagepub.com/doi/10.1177/1932296814555820.

    Article  Google Scholar 

  16. Weiss S, Cheng S. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled. Arch Intern Med. 2003;163:2277–82. Available from: http://archinte.ama-assn.org/cgi/reprint/163/19/2277.pdf.

    Article  CAS  Google Scholar 

  17. Arnolds S, Heise T. Inhaled insulin. Best Pract Res Clin Endocrinol Metab. 2007;21(4):555–71. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1521690X07000590.

    Article  CAS  Google Scholar 

  18. Mohanty RR, Das S. Inhaled insulin - current direction of insulin research. J Clin Diagn Res. 2017;11(4):OE01–2.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Meneghini L, Mersebach H, Kumar S, Svendsen A, Hermansen K. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr Pract. 2011;17(5):727–36. Available from: http://journals.aace.com/doi/abs/10.4158/EP10367.OR.

    Article  Google Scholar 

  20. Meneghini LF. Stepwise addition of prandial insulin. Lancet Diabetes Endocrinol. Elsevier Ltd. 2014;2(1):3–4. Available from: https://doi.org/10.1016/S2213-8587(13)70056-1.

  21. Bode, Bruce; Kyllo, Jennifer; Kaufman FR. Pumping Protocl. A Guide to Insulin Pump Therapy Initiation [Internet]. https://s3.amazonaws.com/medtronic-hcp/Pumping%20Protocol%20-%20a%20Guide%20to%20Insulin%20Pump%20Therapy%20Initiation.pdf. 2007. Available from: https://s3.amazonaws.com/medtronic-hcp/Pumping Protocol - a Guide to Insulin Pump Therapy Initiation.pdf.

  22. Walsh J, Roberts R, Bailey T. Guidelines for optimal bolus calculator settings in adults. J Diabetes Sci Technol. 2011;5(1):129–35.

    Article  Google Scholar 

  23. Walsh J, Roberts R, Bailey T. Guidelines for insulin dosing in continuous subcutaneous insulin infusion using new formulas from a retrospective study of individuals with optimal glucose levels. J Diabetes Sci Technol. 2010;4(5):1174–81.

    Article  Google Scholar 

  24. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8366922.

    Article  Google Scholar 

Suggested/Further Reading

  • American Diabetes Association (ADA). Practical insulin: a handbook for prescribing providers. 3rd ed. Alexandria, VA: American Diabetes Association; 2011.

    Google Scholar 

  • Faradji Hazán RN. Indicar un Esquema Convencional e Intensivo de Insulina. In: Sociedad Mexicana de Nutrición y Endocrinología: Taller de Atención Integral para Pacientes con Diabetes. Manual para Profesores y Manual para Alumnos. Chapter 14. 1st ed. Editorial Permanyer; 2014.

    Google Scholar 

  • Faradji Hazán RN, Díaz Barriga Menchaca AP, Antillón Ferreira, CA. Diabetes en la Población Pediátrica. In: Dorantes y Martínez, SMNE: Endocrinología Clínica. 5th ed. Editorial Manual Moderno; 2016. ISBN 9786074485554.

    Google Scholar 

  • Faradji Hazán RN, E Sainz de la Maza Viadero, Hazán de Jacob y Levy E, Morales Alvarado E, Díaz Barriga Menchaca AP. Chapter 11. Tratamiento integral de la Diabetes Tipo 1. In: Ochoa Martínez C, Madero Fernández del Castillo MA y González Chávez A, SMNE, CMMI: Manual práctico del manejo de la diabetes mellitus y sus complicaciones. 1st ed. Editorial Alfil; 2016. ISBN 9786077411673.

    Google Scholar 

  • Phillips P. Insulin and type 2 diabetes: a simple guide to prevent’stuff ups’. Aust Fam Physician. 2006;35(12):975–8.

    PubMed  Google Scholar 

  • To access useful information and resources about the topic in Spanish consult: http://www.clinicaendi.mx/para-imprimir/.

Download references

Author information

Authors and Affiliations

  1. Clinica EnDi, Mexico City, Mexico

    Raquel N. Faradji & María Elena Sainz de la Maza Viadero

  2. RENACED Diabetes Tipo 1, Mexico City, Mexico

    Raquel N. Faradji & María Elena Sainz de la Maza Viadero

  3. Pathophysiology of the Endocrine System, Escuela de Medicina TEC-ABC, Tecnologico de Monterrey, Centro Medico ABC, Mexico City, Mexico

    Raquel N. Faradji

  4. Sociedad Mexicana de Nutrición y Endocrinología, Mexico, Mexico City, Mexico

    Raquel N. Faradji

  5. Instituto Nacional de Ciencias Médias y Nutrición “Salvador Zubirán”, Mexico City, Mexico

    Ana Paula Díaz Barriga-Menchaca

  6. Didactic Resources for Nutrition, Escuela de Dietetica y Nutricion ISSSTE, Mexico City, Mexico

    María Elena Sainz de la Maza Viadero

Authors
  1. Raquel N. Faradji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana Paula Díaz Barriga-Menchaca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. María Elena Sainz de la Maza Viadero
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Multidisciplinary Diabetes Center, Mexico City, Mexico

    Joel Rodriguez-Saldana

Appendix: Initial Doses for Each Regimen

Appendix: Initial Doses for Each Regimen

Basal insulin

  • 0.2 units/kg/day or 10 units (usually in the evening)

Conventional insulin regimen

  • 0.5 units/kg/day

Divide

Option A

  • 2/3 in am (2/3 NPH, 1/3 rapid or fast acting)

  • 1/3 in pm (1/2 NPH, 1/2 rapid or fast acting)

Option B

  • 1/3 before every meal (1/2 NPH, 1/2 rapid or fast acting)

Basal-bolus insulin regimen

Fixed basal-bolus

  • 0.5 units/kg/day

    • 50% for basal doses

    • 50% for prandial doses, divided in three equal doses. One for each meal.

Flexible basal-bolus

  • 0.5 units/kg/day (total daily dose: TDD)

    • −50% for basal doses

    • −50% for prandial doses

Insulin to carbohydrate ratio (I:CHO ratio)

  • I:CHO ratio = 450/TDD

  • Prandial bolus: Total of carbohydrate grams/I:CHO ratio

Correction factor

  • mg/dL: correction factor = 2000/ TDD

  • mmol/L: correction factor = 100/TDD

  • Pre-meal target glucose: Initially 150 mg/dL (~8 mmol/L), later on 120 mg/dL (~7 mmol/L). If the patient is stable and is able to identify hypoglycemia, target glucose could be lowered to 100 mg/dL (5.55 mmol/L).

  • Post-meal target glucose: 180 mg/dL (10 mmol/L)

  • Correction bolus = (Current glucose − Target glucose)/Correction factor

  • Total bolus: Prandial Bolus + Correction Bolus

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Faradji, R.N., Barriga-Menchaca, A.P.D., Sainz de la Maza Viadero, M.E. (2019). Use of Insulin in Outpatient Diabetes Management. In: Rodriguez-Saldana, J. (eds) The Diabetes Textbook. Springer, Cham. https://doi.org/10.1007/978-3-030-11815-0_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11815-0_35

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-11814-3

  • Online ISBN: 978-3-030-11815-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation